CD4-BFFI: A novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency

Antiviral Research

Volumn 83, Issue 3, 2009, Pages 257-266

  Jekle, Andreas ^a   Chow, Eugene ^a   Kopetzki, Erhard ^b   Ji, Changhua ^a   Yan, Mei Jun ^a   Nguyen, Rosa ^a   Sankuratri, Surya ^a   Cammack, Nick ^a   Heilek, Gabrielle ^a  

^a ROCHE BIOSCIENCE   (United States)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Antibody; CD4 receptor; Fusion inhibitor; HIV 1

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 BIFUNCTIONAL FUSION INHIBITOR; CHEMOKINE RECEPTOR CCR5 MONOCLONAL ANTIBODY; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MARAVIROC; OKT 4; PLERIXAFOR; T 1144; T 651; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY; VIRUS INHIBITION; VIRUS STRAIN;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CELL LINE; HIV FUSION INHIBITORS; HIV-1; HUMANS; RECOMBINANT FUSION PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 68249114530     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.06.005     Document Type: Article

References (51)

1. Allaway G.P., Davis-Bruno K.L., Beaudry G.A., Garcia E.B., Wong E.L., Ryder A.M., Hasel K.W., Gauduin M.C., Koup R.A., McDougal J.S., et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 11 5 (1995) 533-539
2. Berger E.A., Doms R.W., Fenyo E.M., Korber B.T., Littman D.R., Moore J.P., Sattentau Q.J., Schuitemaker H., Sodroski J., and Weiss R.A. A new classification for HIV-1. Nature 391 6664 (1998) 240
3. Berger E.A., Murphy P.M., and Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17 (1999) 657-700
4. Bleul C.C., Wu L., Hoxie J.A., Springer T.A., and Mackay C.R. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 94 5 (1997) 1925-1930
5. Burkly L.C., Olson D., Shapiro R., Winkler G., Rosa J.J., Thomas D.W., Williams C., and Chisholm P. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J. Immunol. 149 5 (1992) 1779-1787
6. Chan D.C., and Kim P.S. HIV entry and its inhibition. Cell 93 5 (1998) 681-684
7. Chen C.H., Matthews T.J., McDanal C.B., Bolognesi D.P., and Greenberg M.L. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J. Virol. 69 6 (1995) 3771-3777
8. Connor R.I., Sheridan K.E., Ceradini D., Choe S., and Landau N.R. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185 4 (1997) 621-628
9. Davison D., Medinas R., Mosier S., Bowling T., Delmedico M., Dwyer J., Cammack N., and Grenberg M. New fusion inhibitor peptides, TRI-999 and TRI-1144, are potent inhibitors of enfuvirtide and T-1249 resistant isolates. XVI International AIDS Conference. Toronto, Canada (2006)
10. De Clercq E., Yamamoto N., Pauwels R., Baba M., Schols D., Nakashima H., Balzarini J., Debyser Z., Murrer B.A., Schwartz D., et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc. Natl. Acad. Sci. U. S. A. 89 12 (1992) 5286-5290
11. De Clercq E., Yamamoto N., Pauwels R., Balzarini J., Witvrouw M., De Vreese K., Debyser Z., Rosenwirth B., Peichl P., Datema R., et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 38 4 (1994) 668-674
12. De Vreese K., Reymen D., Griffin P., Steinkasserer A., Werner G., Bridger G.J., Este J., James W., Henson G.W., Desmyter J., Anne J., and De Clercq I. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Res. 29 2-3 (1996) 209-219
13. Dwyer J.J., Wilson K.L., Davison D.K., Freel S.A., Seedorff J.E., Wring S.A., Tvermoes N.A., Matthews T.J., Greenberg M.L., and Delmedico M.K. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. U. S. A. 104 31 (2007) 12772-12777
14. Erickson-Viitanen E., Abremski K., Solomon K., Levy R., Lam E., Whitcomb J., Lloyd R., Mathis R., Reeves J., and Burns D. Co-receptor tropism, ENV genotype and in vitro susceptibility to CCR5 antagonists during a 14-Day monotherapy study with INCB9471. 15th Conference on Retroviruses and Opportunistic Infections. Boston (2008)
15. Este J.A., and Telenti A. HIV entry inhibitors. Lancet 370 9581 (2007) 81-88
16. Fatkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., Saag M.S., Goebel F.D., Rockstroh J.K., Dezube B.J., Jenkins T.M., Medhurst C., Sullivan J.F., Ridgway C., Abel S., James I.T., Youle M., and van der Ryst E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11 11 (2005) 1170-1172
17. Gallo S.A., Finnegan C.M., Viard M., Raviv Y., Dimitrov A., Rawat S.S., Puri A., Durell S., and Blumenthal R. The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 1614 1 (2003) 36-50
18. Greenberg M.L., and Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54 2 (2004) 333-340
19. Hendrix C.W., Collier A.C., Lederman M.M., Schols D., Pollard R.B., Brown S., Jackson J.B., Coombs R.W., Glesby M.J., Flexner C.W., Bridger G.J., Badel K., MacFarland R.T., Henson G.W., and Calandra G. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquir. Immune Defic. Syndr. 37 2 (2004) 1253-1262
20. Hong Y.L., Wu L.H., Cui M., McMaster G., Hunt III S.W., and Chung F.Z. New reporter cell lines to study macrophage-tropic HIV envelope protein-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 15 18 (1999) 1667-1672
21. Horvath A., Tokes S., Hartman T., Watson K., Turpin J.A., Buckheit Jr. R.W., Sebestyen Z., Szollosi J., Benko I., Bardos T.J., Dunn J.A., Fesus L., Toth F.D., and Aradi J. Potent inhibition of HIV-1 entry by (s4dU)35. Virology 334 2 (2005) 214-223
22. Jacobson J.M., Israel R.J., Lowy I., Ostrow N.A., Vassilatos L.S., Barish M., Tran D.N., Sullivan B.M., Ketas T.J., O'Neill T.J., Nagashima K.A., Huang W., Petropoulos C.J., Moore J.P., Maddon P.J., and Olson W.C. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob. Agents Chemother. 48 2 (2004) 423-429
23. Jacobson J.M., Kuritzkes D.R., Godofsky E., Dejesus E., Larson J.A., Weinheimer S.P., and Lewis S.T. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an Anti-CD4 monoclonal antibody, in HIV-1 infected adults. Antimicrob. Agents Chemother. 53 2 (2008) 450-457
24. Jekle A., Chhabra M., Chow E., Meier S., Sankuratri S., Brandt M., Cammack N., and Heilek G. Resistance to CCR5mAb RoAb3952 is associated with a shift in binding from the extracellular domain 2 to the N-terminus of CCR5. Antiviral Ther. 13 Suppl. 3 (2008) A4
25. Jekle A., Kondru R., Ji C., Chuang K., Swinney D., Rotstein D., Sankuratri S., Cammack N., and Heilek G. CCR5 binding properties of a CCR5 small-molecule inhibitor with high antiviral potency against a maraviroc-resistant HIV-1 strain. Antiviral Ther. 12 S1 (2007) S13
26. Ji C., Brandt M., Dioszegi M., Jekle A., Schwoerer S., Challand S., Zhang J., Chen Y., Zautke L., Achhammer G., Baehner M., Kroetz S., Heilek-Snyder G., Schumacher R., Cammack N., and Sankuratri S. Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities. Antiviral Res. 74 2 (2007) 125-137
27. Ji C., Kopetzki E., Jekle A., Stubenrauch K.G., Liu X., Zhang J., Rao E., Schlothauer T., Fischer S., Cammack N., Heilek G., Ries S., and Sankuratri S. CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability. J. Biol. Chem. 284 8 (2009) 5175-5185
28. Kilby J.M., Hopkins S., Venetta T.M., DiMassimo B., Cloud G.A., Lee J.Y., Alldredge L., Hunter E., Lambert D., Bolognesi D., Matthews T., Johnson M.R., Nowak M.A., Shaw G.M., and Saag M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4 11 (1998) 1302-1307
29. Kopetzki E., Jekle A., Ji C., Rao E., Zhang J., Fischer S., Cammack N., Sankuratri S., and Heilek G. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1. Virol. J. 5 (2008) 56
30. Kuritzkes D.R., Jacobson J., Powderly W.G., Godofsky E., DeJesus E., Haas F., Reimann K.A., Larson J.L., Yarbough P.O., Curt V., and Shanahan Jr. W.R. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. 189 2 (2004) 286-291
31. Lalezari J., Yadavalli G.K., Para M., Richmond G., Dejesus E., Brown S.J., Cai W., Chen C., Zhong J., Novello L.A., Lederman M.M., and Subramanian G.M. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J. Infect. Dis. 197 5 (2008) 721-727
32. Lalezari J., Lederman M., Yadavalli G., Para M., Richmond G., deJesus E., Searle J., Cai W., Roschke V., Zhong J., Hicks C., Freimuth W., and Subrumanian G.M. A phase 1, dose-escalation, placebo-controlled study of a fully human monoclonal antibody (CCR5mAb004) against CCR5 patients with CCR5 tropic HIV-1 infection. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco (2006)
33. Lee B., Sharron M., Montaner L.J., Weissman D., and Doms R.W. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc. Natl. Acad. Sci. U. S. A. 96 9 (1999) 5215-5220
34. Madani N., Perdigoto A.L., Srinivasan K., Cox J.M., Chruma J.J., LaLonde J., Head M., Smith III A.B., and Sodroski J.G. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J. Virol. 78 7 (2004) 3742-3752
35. Marozsan A.J., Kuhmann S.E., Morgan T., Herrera C., Rivera-Troche E., Xu S., Baroudy B.M., Strizki J., and Moore J.P. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338 1 (2005) 182-199
36. Moore J.P., and Doms R.W. The entry of entry inhibitors: a fusion of science and medicine. Proc. Natl. Acad. Sci. U. S. A. 100 19 (2003) 10598-10602
37. Ogert R.A., Wojcik L., Buontempo C., Ba L., Buontempo P., Ralston R., Strizki J., and Howe J.A. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 373 2 (2008) 387-399
38. Pugach P., Marozsan A.J., Ketas T.J., Landes E.L., Moore J.P., and Kuhmann S.E. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361 1 (2007) 212-228
39. Ratner L., Haseltine W., Patarca R., Livak K.J., Starcich B., Josephs S.F., Doran E.R., Rafalski J.A., Whitehorn E.A., Baumeister K., et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313 6000 (1985) 277-284
40. Reimann K.A., Lin W., Bixler S., Browning B., Ehrenfels B.N., Lucci J., Miatkowski K., Olson D., Parish T.H., Rosa M.D., Oleson F.B., Hsu Y.M., Padlan E.A., Letvin N.L., and Burkly L.C. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res. Hum. Retroviruses 13 11 (1997) 933-943
41. Rimsky L.T., Shugars D.C., and Matthews T.J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72 2 (1998) 986-993
42. Schuitemaker H., Koot M., Kootstra N.A., Dercksen M.W., de Goede R.E., van Steenwijk R.P., Lange J.M., Schattenkerk J.K., Miedema F., and Tersmette M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66 3 (1992) 1354-1360
43. Schweighardt B., Roy A.M., Meiklejohn D.A., Grace II E.J., Moretto W.J., Heymann J.J., and Nixon D.F. R5 human immunodeficiency virus type 1 (HIV-1) replicates more efficiently in primary CD4+ T-cell cultures than X4 HIV-1. J. Virol. 78 17 (2004) 9164-9173
44. Tagat J.R., McCombie S.W., Nazareno D., Labroli M.A., Xiao Y., Steensma R.W., Strizki J.M., Baroudy B.M., Cox K., Lachowicz J., Varty G., and Watkins R. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperaz inyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J. Med. Chem. 47 10 (2004) 2405-2408
45. Tasca S., Ho S.H., and Cheng-Mayer C. R5X4 viruses are evolutionary, functional and antigenic intermediates in the pathway of SHIV coreceptor switch. J. Virol. 82 14 (2008) 7089-7099
46. Trkola A., Ketas T.J., Nagashima K.A., Zhao L., Cilliers T., Morris L., Moore J.P., Maddon P.J., and Olson W.C. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75 2 (2001) 579-588
47. Trottier B., Walmsley S., Reynes J., Piliero P., O'Hearn M., Nelson M., Montaner J., Lazzarin A., Lalezari J., Katlama C., Henry K., Cooper D., Clotet B., Arasteh K., Delfraissy J.F., Stellbrink H.J., Lange J., Kuritzkes D., Eron Jr. J.J., Cohen C., Kinchelow T., Bertasso A., Labriola-Tompkins E., Shikhman A., Atkins B., Bourdeau L., Natale C., Hughes F., Chung J., Guimaraes D., Drobnes C., Bader-Weder S., Demasi R., Smiley L., and Salgo M.P. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J. Acquir. Immune Defic. Syndr. 40 4 (2005) 413-421
48. Wang T., Zhang Z., Wallace O.B., Deshpande M., Fang H., Yang Z., Zadjura L.M., Tweedie D.L., Huang S., Zhao F., Ranadive S., Robinson B.S., Gong Y.F., Ricarrdi K., Spicer T.P., Deminie C., Rose R., Wang H.G., Blair W.S., Shi P.Y., Lin P.F., Colonno R.J., and Meanwell N.A. Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. 46 20 (2003) 4236-4239
49. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., and Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46 6 (2002) 1896-1905
50. Westby M., Smith-Burchnell C., Mori J., Lewis M., Mosley M., Stockdale M., Dorr P., Ciaramella G., and Perros M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81 5 (2007) 2359-2371
51. Wood A., and Armour D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem. 43 (2005) 239-271